Skip to main content

Table 1 Descriptive demographic and clinical features of the study groups

From: In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases

  AD-D AD-MCI HC Test value; p
N 22 16 74
Sex, N (M/F) 10/12 11/5 31/43
Age, mean ± SD 72.18 ± 6.27 71.38 ± 10.53 67.15 ± 13.87 F = 1.84; p = 0.16
MMSE, mean ± SD* 17.92 ± 6.70 26.88 ±1.20 T = 4.75; p < 0.001
CDR, mean ± SD* 1.84 ± 0.77 0.50 ± 0.00 T = −7.65; p < 0.001
  1. Abbreviations: AD-D Alzheimer’s disease dementia, CDR Clinical Dementia Rating, HC healthy controls, AD-MCI MCI due to Alzheimer’s disease, MMSE Mini-Mental State Examination
  2. *Neither MMSE nor CDR was available in 3 AD-D patients, who were tested by means of the Montreal Cognitive Assessment test (total MoCA score = 11; 12; 19, respectively)